CytomX Therapeutics, Inc.
(NASDAQ : CTMX)

( )
CTMX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.43%203.201.2%$410.88m
GILDGilead Sciences, Inc.
0.29%73.880.9%$388.27m
CELGCelgene Corporation
-0.26%87.381.2%$331.13m
BIIBBiogen Inc.
0.60%338.911.2%$285.04m
ILMNIllumina, Inc.
-0.15%350.373.5%$238.24m
REGNRegeneron Pharmaceuticals, Inc.
-1.19%383.702.6%$211.99m
EXASExact Sciences Corporation
1.90%74.1425.3%$196.59m
VRTXVertex Pharmaceuticals Incorporated
-0.29%176.601.9%$158.10m
SRPTSarepta Therapeutics, Inc.
-1.06%151.9516.4%$124.69m
AAgilent Technologies, Inc.
0.93%69.571.5%$120.73m
ALXNAlexion Pharmaceuticals, Inc.
0.95%121.972.0%$110.07m
VKTXViking Therapeutics, Inc.
0.98%19.650.9%$100.12m
NKTRNektar Therapeutics
-2.81%56.695.6%$93.69m
ALNYAlnylam Pharmaceuticals, Inc
1.14%94.829.7%$93.23m
BMRNBioMarin Pharmaceutical Inc.
0.21%99.774.4%$92.72m

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.